<code id='7C37876523'></code><style id='7C37876523'></style>
    • <acronym id='7C37876523'></acronym>
      <center id='7C37876523'><center id='7C37876523'><tfoot id='7C37876523'></tfoot></center><abbr id='7C37876523'><dir id='7C37876523'><tfoot id='7C37876523'></tfoot><noframes id='7C37876523'>

    • <optgroup id='7C37876523'><strike id='7C37876523'><sup id='7C37876523'></sup></strike><code id='7C37876523'></code></optgroup>
        1. <b id='7C37876523'><label id='7C37876523'><select id='7C37876523'><dt id='7C37876523'><span id='7C37876523'></span></dt></select></label></b><u id='7C37876523'></u>
          <i id='7C37876523'><strike id='7C37876523'><tt id='7C37876523'><pre id='7C37876523'></pre></tt></strike></i>

          explore

          explore

          author:hotspot    Page View:2697
          Anna Yeo/STAT

          Recently approved gene therapies offer patients one-time, potentially curative treatments for genetic diseases such as sickle cell anemia and beta thalassemia. But “one-time” miracle solutions can often be multi-month affairs, require millions of dollars, and cause painful side effects. What if that doesn’t have to be the case?

          In utero gene editing, or prenatal somatic cell genome editing, envisions treating a fetus diagnosed with a genetic disease before birth, thereby preventing that entire protocol and the onset of symptoms in the first place. It would also challenge the need for the ethically fraught enterprise of embryo editing, as the treatment would only make edits in the DNA of the individual fetus — edits which would not be passed on in a heritable way. 

          advertisement

          Watch this video to learn more about in utero gene editing, how it works, and why scientists believe it might be an advantageous approach to treating certain genetic diseases.

          knowledge

          Drug repurposing or repositioning? The language matters
          Drug repurposing or repositioning? The language matters

          AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

          read more
          FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial
          FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

          MarkJ.Terrill/APAfollow-upstudyofafirst-of-its-kindcancertreatmentmayreflectsystemicbiases,theFoodan

          read more
          Alkermes shareholders re
          Alkermes shareholders re

          MarkLennihan/APAlkermesshareholdersvotedThursdaytore-electallofthedrugmaker’scurrentdirectors,ending

          read more

          FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

          MarkJ.Terrill/APAfollow-upstudyofafirst-of-its-kindcancertreatmentmayreflectsystemicbiases,theFoodan